Richard Schilsky to Naphthalimides
This is a "connection" page, showing publications Richard Schilsky has written about Naphthalimides.
Connection Strength
0.112
-
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
Score: 0.044
-
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
Score: 0.033
-
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb; 6(1):93-101.
Score: 0.009
-
Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(3):267-70.
Score: 0.008
-
Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
Score: 0.007
-
Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther. 1991 Nov; 50(5 Pt 1):573-9.
Score: 0.007
-
Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res. 1988 Jul 15; 48(14):4127-30.
Score: 0.005